Utama › Kanser Payudara Triple-Negatif › Pennsylvania › Philadelphia
Kajian klinikal Kanser Payudara Triple-Negatif di Philadelphia, PA
13 kajian untuk Kanser Payudara Triple-Negatif sedang mencari peserta di lokasi dalam dan sekitar Philadelphia (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Study of AVZO-021 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Avenzo Therapeutics Recruiting Site, Philadelphia
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Mengambil pesertaFasa 3
- Sidney Kimmel Cancer Center at Jefferson ( Site 0049), Philadelphia
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Mengambil pesertaFasa 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Mengambil pesertaFasa 3
- University of Pennsylvania Abramson Cancer Center, Philadelphia
- Lankenau Medical Center, Wynnewood · 7 mi jauh
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Mengambil pesertaFasa 1
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Mengambil pesertaFasa 2/3
- Abramson Cancer Center of The University of Pennsylvania, Philadelphia
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Mengambil pesertaFasa 2
- University of Pennsylvania (U Penn), Philadelphia
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Mengambil pesertaFasa 2
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Mengambil pesertaFasa 2
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
Mengambil peserta
- Thomas Jefferson University Hospital, Philadelphia
Role of the Immune Environment in Response to Therapy in Breast Cancer
Mengambil pesertaKajian pemerhatian
- Abramson Cancer Center, Philadelphia
Kajian Kanser Payudara Triple-Negatif di bandar lain
- Houston, TX42 kajian
- New York City, NY31 kajian
- Nashville, TN28 kajian
- Los Angeles, CA27 kajian
- Boston, MA26 kajian
- San Antonio, TX23 kajian
- St. Louis, MO21 kajian
- Arlington, VA20 kajian
- Atlanta, GA20 kajian
- Dallas, TX18 kajian
- Chicago, IL16 kajian
- Columbus, OH16 kajian
Kajian lain di Philadelphia
- Kanser (semua jenis)59 kajian
- Kanser Payudara56 kajian
- Kanser Paru-paru Bukan Sel Kecil51 kajian
- Kanser Metastatik46 kajian
- Kanser Prostat44 kajian
- Kanser Kolorektal44 kajian
- Kanser Ovari44 kajian
- Kanser Paru-paru36 kajian
- Leukemia Mieloid Akut34 kajian
- Kegagalan Jantung31 kajian
- Kanser Endometrium28 kajian
- Depresi26 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.